



P&T Committee Meeting

Wednesday, January 9, 2013

Lazarus Building, room C621 *

50 W. Town St., Columbus, OH 43215

10:00 AM

- 1) Conflict of Interest Policy (attached)
- 2) Interested party presentations **
- 3) New Business: New PDL Drugs
 - a) CNS – Multiple Sclerosis: Aubagio (teriflunomide tablets), Sanofi
 - b) Gastrointestinal
 - i) Pancreatic Enzymes: Pertzye (pancrelipase delayed-release capsules), Digestive Care
 - ii) Chronic Constipation: Linzess (linaclotide capsules), Forest
 - c) GU – Urinary Antispasmodics: Myrbetriq (mirabegron extended-release tablets), Astellas
 - d) Nasal Preparations:
 - i) Zetonna (ciclesonide nasal aerosol), Sunovion
 - ii) Dymista (azelastine HCl and fluticasone propionate nasal spray), Meda
 - e) Respiratory – COPD: Tudorza Pressair (aclidinium bromide inhalation powder), Forest
- 4) Old Business
 - a) Atypical antipsychotic use in pediatrics and in patients with dementia

* Lazarus Building Security requires that visitors show a photo ID, be signed in by staff, wear a visitor badge and be escorted while in the building. Bags may be searched. Please arrive early for security procedures to be completed

** Any interested party may request to present information to the P&T Committee. Guidelines are posted at <http://jfs.ohio.gov/ohp/bhpp/omdp/pdf/GuidelinesforSubmissions.pdf>.

Ohio Office of Medical Assistance

**Pharmacy and Therapeutics Committee
Conflict of Interest Policy**

Purpose: To require members of the Office of Medical Assistance Pharmacy and Therapeutics Committee to abide by this policy so that scientific and economic data serves as the primary basis in rendering objective decisions about drugs being considered for coverage by Ohio Medicaid.

Definition: A potential “conflict of interest” may exist when a committee member has a relationship with a manufacturer of the medication or class of medications being considered that could inappropriately influence his/her judgment, or the judgment of other members. This may include a relationship with a manufacturer of a drug which competes with the drug under consideration. A relationship with a manufacturer may include any of the following:

- Acceptance of honoraria
- Participation in speaker’s bureau
- Acceptance of support for travel for professional or education activities
- Acceptance of research support
- Relationship valued at \$500 or more with one company
- Consultant arrangement

Policy Statements

1. A member shall not participate in the discussion of an issue that is before the committee unless he/she has first disclosed any potentially relevant conflict of interest.
2. The committee will determine if a specific activity or relationship represents a potential conflict of interest and whether the member disclosing a potentially relevant conflict should continue to participate in the discussion.

Procedure: Committee members must sign this agreement once each year.

Signature _____ Date _____

Printed Name _____